Characterization of quinolone antibacterial-induced convulsions and increases in nuclear AP-1 DNA- and CRE-binding activities in mouse brain

Neuropharmacology

Volumn 38, Issue 5, 1999, Pages 717-723

  Ito, Yoshihisa ^a   Ishige, Kumiko ^a   Aizawa, Masahiro ^a   Fukuda, Hideomi ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Convulsions; Quinolone antibacterials; Transcription factors

Indexed keywords

ENOXACIN; FELBINAC; FENBUFEN; LEVOFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; CONVULSION; CYCLIC AMP RESPONSIVE ELEMENT; DRUG MECHANISM; ELECTROENCEPHALOGRAM; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CYCLIC AMP RECEPTOR PROTEIN; ELECTROENCEPHALOGRAPHY; ENOXACIN; MALE; MICE; NORFLOXACIN; PHENYLACETATES; SEIZURES; TRANSCRIPTION FACTOR AP-1;

EID: 0033036809     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00224-X     Document Type: Article

References (34)

1. Aizawa M., Ito Y., Fukuda H. Pharmacological profiles of generalized absence seizures in lethargic, stargazer and γ-hydroxybutyrate-treated model mice. Neurosci. Res. 29:1997a;17-25.
2. B) receptors in hippocampal long-term potentiation and pathogenesis of absence seizures. Biol. Pharm. Bull. 20:1997b;1066-1070.
3. Akahane K., Kimura Y., Tsutomi Y., Hayakawa I. Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits GABA receptor sites. Antimicrob. Agents Chemother. 38:1994a;2323-2329.
4. Akahane K., Sekiguchi M., Une T., Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites. Antimicrob. Agents Chemother. 33:1989;1704-1708.
5. Akahane K., Tsutomi Y., Kimura Y., Kitano Y. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding. Chemotherapy. 40:1994b;412-417.
6. A receptor in dissociated hippocampal cells of rat. J. Neurophysiol. 66:1991;497-504.
7. Anastasio G.D., Menscer D., Little J.M. Norfloxacin and seizures. Ann. Intern. Med. 109:1988;169-170.
8. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J. Antimicrob. Chemother. 26:1990;219-225.
9. Curran T., Franza B.R. Fos and Jun: the AP-1 connection. Cell. 55:1988;395-397.
10. de Curtis M., Avanzini G. Thalamic regulation of epileptic spike and wave discharges. Funct. Neurol. 9:1994;307-326.
11. Halliwell R.F., Davey P.G., Lambert J.J. The effects of quinolones and NSAIDs upon GABA-evoked currents recorded from rat dorsal root ganglion neurons. J. Antimicrob. Chemother. 27:1991;209-218.
12. A receptors by 4-quinolones. J. Antimicrob. Chemother. 31:1993;457-462.
13. A and ionotropic glutamate receptors. Neuropharmacology. 34:1995;1615-1625.
14. Hori S., Saito A., Shimada J., Ohmori M., Shiba K., Hojo T., Kaji M., Okuda S., Yoshida M., Miyahara T. Effects of T-3262 and its structural derivatives on GABA receptor binding. Chemotherapy. 36(Suppl.9):1988;116-120.
15. A receptor. Neuropharmacology. 35:1996;1271-1277.
16. Ishige K., Aizawa M., Ito Y., Fukuda H. γ-Butyrolactone-induced absence-like seizures increase nuclear CRE- and AP-1 DNA-binding activities in mouse brain. Neuropharmacology. 35:1996;45-55.
17. Ito A., Hirai K., Inoue M., Koga H., Suzue S., Irukura T., Mitsuhashi S. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob. Agents Chemother. 17:1980;103-108.
18. B antagonists block γ-butyrolactone-induced absence seizures and coordinated induction of transcription factors in mouse brain. Tanaka C., Bowery N.G. GABA: Receptors, Transporters and Metabolism. 1996a;313-320 Birkhäuser, Basel.
19. A receptor chloride channel by quinolones and norfloxacin-biphenylacetic acid hybrid compounds. Neuropharmacology. 35:1996b;1263-1269.
20. Kouno K., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activity of AT-2266. Antimicrob. Agents Chemother. 24:1983;78-84.
21. Lukasiuk K., Kaczmark L. AP-1 and CRE DNA binding activities in rat brain following pentylenetetrazole induced seizures. Brain Res. 643:1994;227-233.
22. Montominy M.R., Gonzalez G.A., Yamamono K.Y. Regulation of cAMP-inducible genes by CREB. Trends Neurosci. 13:1990;184-188.
23. Nichols M., Weih F., Schmid W., DeVack C. Phosphorylation of CREB affects its binding to high and low affinity sites, implications for cAMP induced gene transcription. EMBO J. 11:1992;3337-3346.
24. Pennypacker K.R., Hong J.S., McMillian M.K. Pharmacological regulation of AP-1 transcription factor DNA binding activity. FASEB J. 8:1998;475-478.
25. Pennypacker K.R., McMillian M.K., Douglass J., Hong J.S. Ontogeny of kainate-induced gene expression in rat hippocampus. J. Neurochem. 62:1994;438-444.
26. Pennypacker K.R., Walczak D., Thai L., Fannin R., Masan E., Douglass J., Hong J.S. Kainate-induced changes in opioid peptide genes and AP-1 protein expression in the rat hippocampus. J. Neurochem. 60:1993;204-211.
27. Sato K., Matsuura Y., Inoue M., Une T., Osada Y., Ogawa H., Mitsuhashi S. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob. Agents Chemother. 22:1982;548-553.
28. Segev S., Rehavi M., Rubinstein E. Quinolones, theophylline, and diclofenac interactions with the γ-aminobutyric acid receptor. Antimicrob. Agents Chemother. 32:1988;1624-1626.
29. Shirasaki T., Harata N., Nakane T., Akaike N. Interactions of various non-steroidal anti-inflammatories and quinolone antimicrobials on GABA response in rat dissociated hippocampal pyramidal neurons. Brain Res. 562:1991;329-331.
30. Simpson K.J., Brodie M.J. Convulsions related to enoxacin. Lancet. ii:1985;161.
31. Sonnenberg J.L., Mitchelmore C., Macgregor-Leon P.F., Hempstead J., Morgan J.I., Curran T. Glutamate receptor agonists increase the expression of Fos, Fra, and AP-1 DNA binding activity in the mammalian brain. Int. J. Neuropharmacol. 24:1989;72-80.
32. Tsuji A., Sato H., Kume Y., Tamai I., Okezaki E., Nagata O., Kato H. Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob. Agents Chemother. 32:1988;190-194.
33. A receptor inhibition required for quinolone-induced convulsions in mice. J. Antimicrob. Chemother. 34:1994;737-746.
34. Wise R., Andrews J.M., Edwards L.J. In vitro activity of Bay 09867, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 23:1983;559-564.